Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes (Q37724230)

22 August 2017

1 reference

title

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes (English)

1 reference

22 August 2017

0 references

Erin L St Onge

1 reference

22 August 2017

Shannon A Miller

series ordinal

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

801-806

1 reference

Standards of medical care in diabetes--2010.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481281

10.1517/14712598.2010.481281

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference